Abstract | BACKGROUND:
Tamoxifen may be a viable treatment option for idiopathic retroperitoneal fibrosis (iRPF) but data are limited and its long-term safety and efficacy is unclear. We describe the long-term course and outcomes in a large group of patients with iRPF treated with tamoxifen monotherapy. METHODS: This is a single-center prospective, observational study of 55 patients with iRPF treated with tamoxifen for 2years from April 1998 through April 2011. Measurements included clinical improvement, laboratory parameters and follow-up computed tomographic (CT) scanning. Treatment success was the composite endpoint of clinical improvement, mass regression and definite resolution of ureteral obstruction. RESULTS: Forty-seven (85%) patients reported substantial resolution of symptoms after median treatment duration of 3.0weeks (IQR 1.4-4.8weeks). Repeated CT scanning showed mass regression in 39 (71%) patients at 4months and 47 (85%) patients at 8months of follow-up, respectively. Nineteen (34.5%) patients did not meet the composite endpoint of treatment success, 56% of whom responded satisfactorily to second-line immunosuppressive treatment. Recurrence-free survival in patients with treatment success after post-treatment follow-up of 21months (IQR 9.0-35.0months) was 68%. Tamoxifen was well tolerated. Pulmonary embolism occurred in 2 patients receiving tamoxifen and in one patient receiving second-line treatment. CONCLUSION:
Tamoxifen is a safe and viable therapeutic option in the treatment of iRPF.
|
Authors | E F H van Bommel, L G Pelkmans, H van Damme, T R Hendriksz |
Journal | European journal of internal medicine
(Eur J Intern Med)
Vol. 24
Issue 5
Pg. 444-50
(Jul 2013)
ISSN: 1879-0828 [Electronic] Netherlands |
PMID | 23246124
(Publication Type: Journal Article, Observational Study)
|
Copyright | Copyright © 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Estrogen Antagonists
- Tamoxifen
|
Topics |
- Aged
- Estrogen Antagonists
(administration & dosage, adverse effects)
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Prospective Studies
- Retroperitoneal Fibrosis
(diagnostic imaging, drug therapy)
- Tamoxifen
(administration & dosage, adverse effects)
- Time Factors
- Tomography, X-Ray Computed
- Treatment Outcome
|